CRESTWOOD, KY, 5 July 2023: Liberate Medical, an emerging leader in the development of novel non-invasive neurostimulation devices focused on transforming respiratory care, announced today the successful closure of its $6.2M Series B financing round. The funding was co-led by a large strategic investor and Scientific Health Development, who will both join Liberate Medical’s Board, solidifying Liberate Medical’s position as a leading innovator in respiratory and critical care.
Liberate Medical’s VentFree Respiratory Muscle Stimulator is the only non-invasive, breath synchronized, neuromuscular electrical stimulator intended to prevent expiratory muscle atrophy in mechanically ventilated patients. A key focus of the funding will be to support the pivotal clinical trial of VentFree, known as the PREVENT trial. The PREVENT trial aims to demonstrate that VentFree reduces the…